|Bid||145.93 x 900|
|Ask||146.09 x 800|
|Day's range||145.02 - 147.00|
|52-week range||96.42 - 164.76|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||173.86|
Although 30 states have legalized cannabis in some capacity, the federal scheduling of pot is a major headache for businesses and medical patients.
Despite generally being a voice of opposition, seniors using medical cannabis for pain relief revealed intriguing results in a new survey.
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
As Canada marches toward recreational legalization for marijuana, Canopy CEO Bruce Linton is optimistic about marketing beverages and sleep-aids to a broader audience.
VANCOUVER, British Columbia, June 27, 2018-- Isodiol International Inc., a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods ...
The DEA must make a final scheduling decision before the drug can be soldDr. The Food and Drug Administration approved the U.S.’s first cannabis-derived drug on Monday, in a move that may make the path to approval clearer for other companies working in the space. The drug, GW Pharmaceuticals’ epidiolex, is intended for seizures associated with two rare types of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
The U.S. Food and Drug Administration approved the first prescription drug derived from the marijuana plant, as a treatment for rare forms of epilepsy that primarily afflict children. PLC’s Epidiolex, also known as cannabidiol, to reduce seizures associated with forms of epilepsy known as Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older. Cannabidiol is derived from the cannabis plant, also known as marijuana.
GW Pharmaceuticals plc (GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs).
VANCOUVER , June 25, 2018 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVT) ("Harvest One" or the "Company") has signed a binding Share Sale Agreement ("SSA") with Australian-based MMJ PhytoTech Limited ("MMJ") for the purchase of 100% of Israeli-based PhytoTech Therapeutics Ltd ("PhytoTech" or "PTL"). The transaction will be a combination of cash and shares. Upon completion, $1 million in cash and $7 million in Harvest One common shares issued at the then 10-day volume weighted average closing price, will be paid to MMJ.